FORT MYERS, Fla., Nov. 22, 2024 /PRNewswire/ -- A landmark in cancer treatment has come full circle, as the U.S. Food and Drug Administration (FDA) approved revumenib, a revolutionary drug for relapsed or refractory acute leukemia with a KMT2A translocation on November 15, 2024. This...
Groundbreaking New FDA-Approved Drug for Acute Leukemia First Administered at Florida Cancer Specialists & Research Institute Sarasota Drug Development Unit
Seaking AlphaSeeking Alpha / Seaking Alpha 5 hours ago 1 Views
Comments